Search Results
Your search for ,ARE matches 21644 pages
Showing 13101 - 13150Next-Generation Genitourinary Oncology: Keeping One’s Powder Dry
There is a new yin-yang of management in genitourinary oncology, with the balance of opposing power focused among cancer cells, kinase inhibition, and lymphocyte function, representing a shift in the fashions of treatment somewhat away from chemotherapy. This linear progress has been complicated...
Attrition High but Positive Trends Observed in Web-Based Intervention Addressing Caregiver Burden
High attrition but positive trends such as increased “benefit finding” were observed with a Web-based intervention designed to address the psychosocial burden on informal caregivers, according to Allison J. Applebaum, PhD, a licensed clinical psychologist at Memorial Sloan Kettering Cancer Center...
How ASCO’s CancerLinQ Discovery™ Will Help Speed Research Advances and Improve Patient Outcomes
This past November, ASCO announced the launch of CancerLinQ Discovery™, a big data learning platform physicians and researchers can use to analyze highly curated, de-identified, real-world cancer care data sets to broaden their clinical knowledge about specific cancers and eventually improve...
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer With Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the management of oropharyngeal cancer. The guideline, “Radiation therapy for oropharyngeal squamous cell carcinoma: An ASTRO Evidence-based Clinical Practice Guideline,” was published by Sher et ...
AACR Introduces New Incoming Officers of the Associate Member Council
The American Association for Cancer Research (AACR) issued congratulations to Allison S. Betof, MD, PhD, on her election to Chairperson-elect of the Associate Member Council (AMC) of AACR. Dr. Betof assumed office at the AACR Annual Meeting earlier this month and will serve as Chairperson-elect...
Dual HER2 Targeting of HER2-Positive Metastatic Colorectal Cancer Shows Clinical Benefit
The combination of trastuzumab (Herceptin) plus lapatinib (Tykerb) achieved positive results in patients with heavily pretreated, HER2-positive metastatic colorectal cancer, according to the final results of the phase II HERACLES-A trial. This two-pronged, HER2-directed approach achieved clinical...
FDA Removes Risk Evaluation and Mitigation Strategy Requirements for Erythropoiesis-Stimulating Agents
On April 13, the U.S. Food and Drug Administration (FDA) removed the risk evaluation and mitigation strategy (REMS) requirements for the use of epoetin alfa and darbepoetin alfa to treat patients with anemia due to associated myelosuppressive chemotherapy. The Agency's announcement regarding...
Satisfaction With Surgical Decision-Making in Women Considering Contralateral Prophylactic Mastectomy for Breast Cancer
In a study reported in JAMA Surgery, Katz et al found that most patients considering contralateral prophylactic mastectomy for stage 0 to II breast cancer were satisfied with surgical decision-making. Most surgeons discussed contralateral prophylactic mastectomy and most did not recommend against...
Predicting Metastatic Disease After Radical Prostatectomy
An individual patient-level meta-analysis has shown that the Decipher® (GenomeDx) genomic classifier is capable of distinguishing risk groups for metastatic disease after radical prostatectomy for prostate cancer. The study was reported by Spratt and colleagues in the Journal of Clinical...
Study Finds Vaccine-Chemotherapy Combination Prolongs Overall Survival in Glioblastoma
Despite highly aggressive therapy that includes maximal tumor resection, high-dose radiation, and temozolomide chemotherapy, the prognosis for patients with newly diagnosed glioblastoma is dismal, with a median survival of less than 15 months, prompting researchers to study novel approaches to...
U.S. Preventive Services Task Force Seeks Comments on Draft Recommendation Statement on Screening for Prostate Cancer
On April 11, the U.S. Preventive Services Task Force (USPSTF) posted for public comment a draft recommendation statement and three draft evidence reviews on screening for prostate cancer. Through this draft recommendation, the Task Force is providing clinicians and their patients with...
ASCO Research Statement: Tapping the Potential of Observational Research
In a research statement reported in the Journal of Clinical Oncology by Visvanathan et al, ASCO has outlined steps for incorporating high-quality observational research into the evidence base for clinical decision-making. As stated by the authors: “ASCO believes that high-quality...
Preclinical Research Suggests Potential Therapy for 'Chemobrain'
Findings offered by a University of Kansas (KU) researcher at the national meeting of the American Chemical Society in early April suggest a possible therapeutic intervention for “chemobrain,” the cognitive impairment that plagues up to a third of cancer patients following chemotherapy. ...
New ACS CAN Report Examines Expected Patient Costs for Common Cancer Diagnoses
On April 11, the American Cancer Society Cancer Action Network (ACS CAN) released its first report examining the costs of treating cancer, specifically the out-of-pocket portion patients face. The report, released at the organization’s annual national policy forum, found U.S. cancer patients...
Spanish Trial Shows Benefit of Vinflunine Maintenance in Advanced Urothelial Carcinoma
In a Spanish phase II trial reported in The Lancet Oncology, García-Donas et al found that maintenance therapy with vinflunine improved progression-free survival vs best supportive care alone in patients with advanced urothelial carcinoma with disease control on first-line chemotherapy....
Trends in Thyroid Cancer Incidence and Mortality in the United States
In a study of Surveillance, Epidemiology, and End Results-9 (SEER-9) data reported in JAMA, Lim et al found that both thyroid cancer incidence and mortality have increased over recent decades, reflecting increases in papillary thyroid cancer incidence and mortality. These findings suggest that the...
Potential Therapeutic Target for Malignant Teratoid/Rhabdoid Tumors Identified in Preclinical Study
Using state-of-the-art gene-editing technology, scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have discovered a promising target to treat atypical teratoid/rhabdoid tumor, a highly aggressive and therapy-resistant brain tumor that mostly occurs in infants. They found...
Breast Cancer Treatment Options Vary Widely in Cost-Effectiveness
A study published by Smith et al in the Journal of the National Cancer Institute indicates that different therapies for early-stage breast cancer have very different relative values. Some therapies may have fewer complications and be much less expensive than others. Women may be making treatment...
Study Finds Link Between Telomere Length and Neighborhood Circumstances
Researchers at Fox Chase Cancer Center have begun to establish a biological basis for the long-held but not well-tested theory that neighborhood exposures can impact health outcomes. Shannon Lynch, PhD, MPH, Assistant Professor in the Cancer Prevention and Control Program at Fox Chase, led a team...
Annual Report to the Nation: Cancer Death Rates Continue to Decline
Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975–2014, published by Jemal et al in the Journal of the National Cancer Institute. The report...
Studies Find Disparity in Life Expectancy Widening Between Wealthy and Poor Americans
To better understand the conditions and mechanisms driving health disparities in the United States, The Lancet partnered with physicians and public health researchers from the City University of New York, Harvard Medical School, Cornell University, Yale School of Medicine, and the New York...
FDA Grants Marketing Authorization for Ipsogen JAK2 RGQ PCR Kit to Detect JAK2 Genetic Mutations
The U.S. Food and Drug Administration (FDA) has granted marketing authorization to the ipsogen JAK2 RGQ PCR Kit, manufactured by QIAGEN GmbH, to detect mutations affecting the Janus tyrosine kinase 2 (JAK2) gene. This is the first FDA-authorized test intended to help physicians in evaluating...
AACR 2017: Telomere Length May Predict Cancer Risk, According to Large Epidemiologic Study
The length of the telomeres that protect the tips of chromosomes may predict cancer risk and be a potential target for future therapeutics, University of Pittsburgh Cancer Institute (UPCI) scientists reported at the 2017 American Association for Cancer Research (AACR) Annual Meeting in...
AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Interim results from the phase Ib/II FB-10 clinical trial of neratinib given in combination with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1, Kadcyla) were reported in a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, according...
Ribociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
On March 13, the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) was approved for use in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast ...
Expect Questions About Colorectal Cancer Among Younger Adults
Publicity surrounding a recent study showing a sharp increase in colorectal cancer among young people, even those in their 20s,1 may result in increased patient visits and questions. Among people aged 20 to 39, colon cancer rates have increased 1% to 2.4%, and rectal cancer rates have increased...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
Practice-Changing Research: Making Palliative Care a Routine Part of Cancer Care in the United States and Abroad
With its recently issued clinical practice guideline update, reviewed in this issue of The ASCO Post, ASCO has spoken: Interdisciplinary palliative care teams improve the outcomes of cancer care; patients live longer and feel better.1 There is no doubt. Multiple well-designed studies show the...
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on integration of palliative care into standard oncology care.1 This update of a 2012 ASCO provisional clinical opinion2 is based on an Expert Panel’s systematic review of data reported between...
Cardiac Dysfunction in Survivors of Adult Cancers
The success of cancer therapy has led us to an interesting place. Patients with cancer are certainly concerned about collateral damage that may occur with the treatment of their condition; however, impressive improvements in survival with treatment of many cancers are so compelling that these...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers.1 Recommendations were developed by an expert panel...
Fred Hutchinson’s Paulovich Laboratory to Lead Protein Assay Work for National Cancer Moonshot
The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, which represents a partnership among the National Cancer Institute (NCI), the Department of Defense, and the Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research...
ASCO Congratulates Seema Verma on Confirmation as CMS Administrator
“ASCO congratulates Seema Verma for her confirmation as Administrator of the Centers for Medicare & Medicaid Services (CMS). Administrator Verma is now in a key position to lead the agency during the next phase of health-care reform in the United States and to help ensure that millions of...
Leading Oncology Professional Societies Launch CancerLinQ® Ambassadors Program
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, and the Oncology Nursing Society (ONS) have recently formed the CancerLinQ® Ambassadors Program. This new collaboration is a national practice engagement initiative that will provide on-the-ground support and guidance to CancerLinQ...
Conquer Cancer Foundation Honors 65 Young Oncology Professionals With Merit Awards
The Conquer Cancer Foundation of ASCO (CCF) is pleased to announce the recipients of its 2017 CCF Merit Awards in Gastrointestinal Cancers, Cancer Survivorship, Genitourinary Cancers, Immuno-Oncology, and Quality Care. The following 65 young researchers, recognized for the scientific merit of their ...
FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....
Expert Point of View: Al Covens, MD
Al Covens, MD, Professor and Chair of Gynecologic Oncology at the University of Toronto, and Head of Gynecologic Oncology at Sunnybrook Health Science Centre, commented on the phase II findings of axalimogene filolisbac: “As almost all cervical cancers are human papillomavirus (HPV)-related, this...
Listeria-Based Immunotherapy Improves Survival in Metastatic Cervical Cancer
Overall survival in recurrent, metastatic cervical cancer was substantially extended with a Listeria-based immunotherapy approach that targets the human papillomavirus (HPV), investigators reported at the Society of Gynecologic Oncology Annual Meeting.1 Of 50 evaluable patients, 19 were alive at...
Expert Point of View: Alessandro Volpe, MD
Formal discussant of this abstract, Alessandro Volpe, MD, of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, commented that nephron-sparing surgery is recommended for clinical stage T1 tumors; however, when compared with ablation, the advantages of...
Evolving Role for Cryoablation in Treating Small Renal Masses
Selected “healthy” patients with clinical T1 renal cell carcinoma may be safely treated with percutaneous cryoablation, according to a single-center study of experience at the Mayo Clinic.1 “In healthier patients, our experience shows that cryoablation achieved good short-term oncologic control...
Young Women With Metastatic Breast Cancer: Unique Needs and Concerns
Patients with breast cancer who perceive having enough and the right kinds of social support tend to be less stressed, although a paucity of research exists on the social support needs of young women with metastatic breast cancer, according to Amanda Ginter, PhD. Dr. Ginter, Assistant Professor in ...
New Constructs for Use in the Identification of Depression in Older Patients With Cancer
Elderly patients with cancer are far less likely to be diagnosed with depression than patients in any other age group for two primary reasons: There is an overlap between cancer symptoms/treatment side effects and the diagnostic criteria for depression, and older adults are more likely to present...
CancerLinQ: Big Data for Quality Benchmarking
At this year’s ASCO Quality Care Symposium, CancerLinQ’s Vice President and Medical Director, Robert S. Miller, MD, shed light on CancerLinQ’s current and future value in the oncology community.1 Dr. Miller opened by explaining to the audience that CancerLinQ™ is an instrument for quality...
Harnessing Implementation Science to Improve Cancer Care Delivery
Implementation science encompasses the study of methods to accelerate integration of evidence into practice and policy to improve health-care outcomes. At the 2017 ASCO Quality Care Symposium, Sandra A. Mitchell, PhD, CRNP, of the Division of Cancer Control and Population Sciences at the National...
FDA Approves Avelumab for Metastatic Merkel Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (Bavencio) on March 23, 2017, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy. Avelumab is a...
AACR 2017: PRMT1 Identified as Potential Druggable Target for Pancreatic Cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma, according to results presented by Giuliani et al the 2017 Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC (Abstract 3016)....
AACR 2017: Minority Patients With Colorectal Cancer Report Higher Burden of Poor Quality-of-Life Than Whites
A study presented by Hildebrandt et al at the 2017 Annual Meeting of the American Association of Cancer Research (AACR; Abstract 990) revealed several findings about racial disparities in health-related quality of life among colorectal cancer patients. Hispanics and blacks had a higher burden of...
AACR 2017: Combination Immunotherapies Show Clinical Activity in Metastatic RCC in Pilot Study
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (RCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. The results of...
AACR 2017: Ipilimumab/CVA21 Combination Treatment Shows Promise in Advanced Melanoma
Treatment with a combination of ipilimumab (Yervoy) and coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior treatment with an immune checkpoint inhibitor, and fewer-than-anticipated...
